Shilpa Medicare hits 52-week high on successful trial of fatty liver drug

Shilpa Medicare jumped 6.40% to Rs 741.90 after the company informed that it has successfully completed phase-3 clinical studies of its product SMLNUD07 - Nor Ursodeoxycholic Acid (NorUDCA) tablets.